Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
Bioconjugate Chemistry|June 1, 2018
Highly Potent Clickable Probe for Cellular Imaging of MDM2 and Assessing Dynamic Responses to MDM2-p53 InhibitionHonorine Lebraud, Richard A Noble, Nicole Phillips, et al.
BMC Cancer|February 1, 2020
Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patientsVahinipriya Manoharan, Eric Hamilton Karunanayake, Kamani Hemamala Tennekoon, et al.
Clinical Lung Cancer|February 22, 2015
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential BiomarkerRodryg Ramlau, Michael Thomas, Silvia Novello, et al.
American Journal of Cancer Research|October 13, 2022
<i>In vitro</i> and <i>in vivo</i> study of GSK2830371 and RG7388 combination in liver adenocarcinomaChiao-En Wu, Chiao-Ping Chen, Yi-Ru Pan, et al.
Cancers|August 7, 2021
WIP1 Inhibition by GSK2830371 Potentiates HDM201 through Enhanced p53 Phosphorylation and Activation in Liver Adenocarcinoma CellsChiao-En Wu, Chen-Yang Huang, Chiao-Ping Chen, et al.
Cancers|February 10, 2026
Correction: Wu et al. WIP1 Inhibition by GSK2830371 Potentiates HDM201 Through Enhanced p53 Phosphorylation and Activation in Liver Adenocarcinoma Cells. <i>Cancers</i> 2021, <i>13</i>, 3876Chiao-En Wu, Ahmed Khairallah Mahdi, Chen-Yang Huang, et al.
Cancer Medicine|August 16, 2018
Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumorMiriam Franklin, Lucy Gentles, Elizabeth Matheson, et al.
Cancers|October 23, 2021
HCV Activates Somatic L1 Retrotransposition-A Potential Hepatocarcinogenesis PathwayPraveen D Sudhindar, Daniel Wainwright, Santu Saha, et al.
Oncotarget|May 3, 2017
Functional characterisation of a novel ovarian cancer cell line, NUOC-1Aiste McCormick, Eleanor Earp, Katherine Elliot, et al.
Leukemia|April 10, 2024
Combination p53 activation and BCL-x<sub>L</sub>/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemiaHayden L Bell, Helen J Blair, Samantha J Jepson Gosling, et al.
Pageof 8